Adial Pharmaceuticals Inc
NASDAQ:ADIL
Adial Pharmaceuticals Inc
NASDAQ:ADIL
Price:
1.69
USD
-2.31%
Market Cap:
$2.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
US |
|
China Logistics Property Holdings Co Ltd
HKEX:1589
|
CN |
|
D
|
Daeduck Co Ltd
KRX:008060
|
KR |
|
National Cinemedia Inc
NASDAQ:NCMI
|
US |
|
Fras Le SA
BOVESPA:FRAS3
|
BR |
|
M
|
Mitsui E&S Co Ltd
SWB:MU1
|
JP |
|
Alexander Marine Co Ltd
TWSE:8478
|
TW |
|
Mullen Automotive Inc
NASDAQ:MULN
|
US |
|
Chengdu Hi-tech Development Co Ltd
SZSE:000628
|
CN |
|
M
|
MLP Group SA
WSE:MLG
|
PL |
|
Yadea Group Holdings Ltd
HKEX:1585
|
CN |
|
Techno Associe Co Ltd
TSE:8249
|
JP |
|
Xiamen Jiarong Technology Co Ltd
SZSE:301148
|
CN |
|
G
|
Greenbank Capital Inc
CNSX:GBC
|
CA |
|
RHB Bank Bhd
KLSE:RHBBANK
|
MY |
|
Rackspace Technology Inc
NASDAQ:RXT
|
US |
|
Annica Holdings Ltd
SGX:5AL
|
SG |
|
M
|
Morgan Stanley Direct Lending Fund
NYSE:MSDL
|
US |
|
CVC Ltd
ASX:CVC
|
AU |
|
Unitil Corp
NYSE:UTL
|
US |
|
Cholamandalam Investment and Finance Company Ltd
NSE:CHOLAFIN
|
IN |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of ADIL.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ADIL
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
ADIL Competitors Multiples
Adial Pharmaceuticals Inc Competitors
Adial Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
2.4m USD | 0 | -0.2 | 0.4 | 0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 13.4 | 42.5 | 28.7 | 30.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 5.4 | 31.2 | 17.2 | 24.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 4.6 | 16.4 | 10.1 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 2.6 | 20.6 | 7.9 | 10.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
